‘Prevalence of Tourette syndrome’

J. Millichap

DOI: https://doi.org/10.1111/j.1469-8749.1999.tb00617.x

1999-05-01

Developmental Medicine & Child Neurology

Abstract:‘Prevalence of Tourette syndrome’ SIR–I wish to comment on Professor Traverse’s recent correspondence regarding the prevalence of Tourette syndrome (TS), published in Developmental Medicine and Child Neurology 40: 847. In agreement with the views of Professor Traverse, I have proposed a parallel between the increased usage of neurostimulants, especially methylphenidate (MPH) and the increased prevalence of TS in the US since the 1970s1. Furthermore, the remarkably large percentage of patients with TS and comorbid attention-deficit–hyperactivity disorder (ADHD) suggests that MPH is a major, probably the most common, precipitating cause of TS and tics in the US1. In a recent letter to the Journal of the Royal Society of Medicine, submitted in November 1998, I indicated that the increase in the prevalence of TS noted in the US would not be expected in the UK, because MPH was not generally prescribed2. At a meeting in Tunbridge Wells, England, in the 1970s, as a speaker and a privileged guest of the late Dr Ronald Mac Keith, I was criticized, even gently scolded, for my interest and research in ADHD, then called minimal brain dysfunction. Dr Mac Keith expressed the opinion that the entity was overemphasized in the US and did not exist in the UK at that time. In recent years the diagnosis of ADHD has received limited attention in the UK, and my British colleagues have begun to treat it with MPH3. The relation between MPH and TS is controversial. A review article from the National Institute of Mental health (NIMH), Bethesda, US, tends to minimize the risk of neurostimulant medication in patients with tics and TS4. The authors condone the use of neurostimulants but caution that parental informed consent should be obtained, a practice that could be questioned on ethical grounds. An estimated 50 to 80% of patients with TS have ADHD, and the use of MPH is cited as the cause of tics in more than 25% of children with ADHD5. Contrary to the NIMH review, evidence favors avoidance of the use of MPH in patients with a personal or family history of TS1, and dosage in treatment of ADHD should be conservative.